High-Dose Stereotactic Radiation for Prostate Cancer

Status Completed

Clinical Trial Summary

This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To assess treatment related gastrointestinal (GI) and genitourinary (GU) toxicity for patients who undergo SBRT for localized prostate cancer.

SECONDARY OBJECTIVES:

I. Follow quality of life after SBRT using Expanded Prostate Cancer Index Composite (EPIC) and American Urological Association (AUA) scores.

II. Assess biochemical control after high-dose SBRT.

OUTLINE:

Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-12 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1.5, 4, 8, and 12 months, every 6 months for 4 years, and then annually thereafter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01664130
Study type	Interventional
Source	Case Comprehensive Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	July 2012
Completion date	January 12, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02217709` - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer	Phase 2
Completed	`NCT03077659` - Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer	Phase 2
Active, not recruiting	`NCT03624660` - Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer	N/A
Completed	`NCT01054079` - Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer	Phase 2
Terminated	`NCT00512668` - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer	Phase 1
Completed	`NCT00087139` - Ixabepilone in Treating Patients With Metastatic Prostate Cancer	Phase 2
Completed	`NCT00182052` - Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer	Phase 3
Active, not recruiting	`NCT03511196` - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	Early Phase 1
Active, not recruiting	`NCT01655836` - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer	Phase 1
Terminated	`NCT03535675` - Muscadine Plus (MPX) In Men With Prostate Cancer	Phase 3
Terminated	`NCT01866423` - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Completed	`NCT02234921` - Pilot Study of DRibble Vaccine for Prostate Cancer Patients	Phase 1
Completed	`NCT01468532` - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03686683` - Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer	Phase 3
Active, not recruiting	`NCT03689699` - Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)	Phase 1/Phase 2
Recruiting	`NCT04694924` - Prospective Prostate Cancer and Patient-reported Outcomes Registry
Active, not recruiting	`NCT04909294` - Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma	N/A
Completed	`NCT02225925` - Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound	N/A
Completed	`NCT01949519` - Docetaxel and Lycopene in Metastatic Prostate Cancer	Phase 1
Completed	`NCT01433913` - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery	Phase 2